SSA
ESLAW icon

Schonfeld Strategic Advisors’s Estrella Immunopharma Warrant ESLAW Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ESLAW Stock Details ESLAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,000
Closed -$4K – 2647
2022
Q1 		$4K Hold
20,000
– – ﹤0.01% 2481
2021
Q4 		$10K Buy
+20,000
New +$9.85K ﹤0.01% 2038

Other funds holding ESLAW

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

Schonfeld Strategic Advisors's ESLAW Position: Q3 2023 in Review

Schonfeld Strategic Advisors sold out of Estrella Immunopharma Warrant (ESLAW) in Q3 2023, closing a stake of 19,500 shares — an estimated $1.02K sold.

Schonfeld Strategic Advisors first reported a position in ESLAW in Q2 2022 and held it in 5 quarters. The position peaked at $5K in Q2 2022. 11 funds tracked by Wall St. Rank hold ESLAW as of Q3 2023.

  • Schonfeld Strategic Advisors reported no remaining Estrella Immunopharma Warrant position as of Q3 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 19,500 Estrella Immunopharma Warrant shares in Q3 2023, an estimated $1.02K.
  • Schonfeld Strategic Advisors first reported a position in Estrella Immunopharma Warrant in Q2 2022 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Estrella Immunopharma Warrant position peaked at $5K in Q2 2022.
  • 11 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q3 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.